Methodology of therapeutic trials in COPD

Clinical Management of Chronic Obstructive Pulmonary Disease

Volumn , Issue , 2002, Pages 255-285

  Lacasse, Yves ^a   Guyatt, Gordon H ^b  

^a LAVAL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 12344259035     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. Thom TJ. International comparisons in COPD mortality. Am Rev Respir Dis 1989; 140:S27–S34.
2. Lacasse Y, Brooks D., Goldstein RS. Trends in the epidemiology of COPD in Canada, 1980 to 1995. Chest 1999; 116:306–313.
3. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77–S120.
4. Cooper JD, Lefrak SS. Is volume reduction surgery appropriate in the treatment of emphysema? Yes. Am J Respir Crit Care Med 1996; 153:1201–1204.
5. Make BJ, Fein AM. Is volume reduction surgery appropriate in the treatment of emphysema? No. Am J Respir Crit Care Med 1996; 153:1205–1207.
6. Tonelli MR, Benditt JO, Albert RK. Clinical experimentation: lessons from lung volume reduction surgery. Chest 1996; 110:230–238.
7. Lomas DA, Caine N, Wells FC on behalf of the Lung Volume Reduction Surgery Trial Project Team. Health technology assessment: time for a randomised controlled trial of the role of lung volume reduction surgery in the treatment of emphysema. The Lung Volume Reduction Surgery Trial Project Team. Thorax 1997; 52:755–756.
8. Miller JD, Malthaner RA, Goldsmith CH, Cox G, Higgins D, Stubbing D, Kitching A, Newman TE, McDonald E. Lung volume reduction for emphysema and the Canadian Lung Volume Reduction Surgery (CLVR) Project. Can Respir J 1999; 6: 26–32.
9. Utz JP, Hubmayr RD, Deschamps C. Lung volume reduction surgery for emphysema: out on a limb without a NETT. Mayo Clin Proc 1998; 73:552–566.
10. The European Respiratory Society Task Force. Optimal assessment and management of chronic obstructive disease. Eur Respir J 1995; 8:1398–1420.
11. Société de Pneumologie de Langue Française—1996. Recommandations pour la prise en charge des bronchopneumopathies obstructives chroniques. Rev Mal Respir 1997; 14(Suppl 2P):7–91.
12. The COPD Guidelines group of the Standards of Care Committee of the British Thoracic Society. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997: 52(Suppl 5):S1–S28.
13. Tougaard L, Krone T, Sorknaes A, Ellegaard H, and the PASTMA group. Economic benefits of teaching patients with chronic obstructive pulmonary disease about their illness. Lancet 1992; 339:1517–1520.
14. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315:725–729.
15. Boulet LP, Turcotte H, Hudon C, Carrier G, Maltais F. Clinical, physiological and radiological features of asthma with incomplete reversibility of airflow obstruction compared with those of COPD. Can Respir J 1998; 5:270–277.
16. Pizzichini E, Pizzichini MMM, Gibson P, Paramerwaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE. Sputum eosinophilia predicts benefits from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511–1517.
17. Cambach W, Wagenaar RC, Koelman TW, Ton van Keimpema ARJ, Kemper HCG. The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis. Arch Phys Med Rehabil 1999; 80:103–111.
18. Pauwels RA, Löfdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992; 5:1254–1261.
19. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HAM, Renkema TEJ, Postma DS, Similowski T, Akkermans RP, Pasker-de Jong PCM, Dekhuijzen PNR, van Herwaarden CLA, van Weel C. Long-term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999; 54:7–14.
20. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53:477–482.
21. Burge PS. EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Thorax 1999; 54:287–288.
22. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Thorax 1998; 53:137–147.
23. Celli BR. Pulmonary rehabilitation and lung volume reduction surgery in the treatment of patients with chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1998; 53:471–479.
24. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. Chest 1997; 112:1363–1396.
25. American Thoracic Society. Lung volume reduction surgery. Am J Respir Crit Care Med 1996; 154:1151–1152.
26. Benditt JO, Albert RK. Surgical options for patients with advanced emphysema. Clin Chest Med 1997; 18:577–593.
27. Sciurba FC. Early and long-term functional outcomes following lung volume reduction surgery. Clin Chest Med 1997; 18:259–276.
28. American Thoracic Society. Pulmonary rehabilitation—1999. Am J Respir Crit Care Med 1999; 159:1666–1682.
29. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ; Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348: 1115–1119.
30. Lacasse Y, Guyatt GH, Goldstein RS. The components of a respiratory rehabilitation program: a systematic overview. Chest 1997; 111:1077–1088.
31. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychological outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122:823–832.
32. Punzal PA, Ries AL, Kaplan RM, Prewitt L. Maximum intensity exercise training in patients with chronic obstructive pulmonary disease. Chest 1991; 100:618–623.
33. Maltais F, Leblanc P, Jobin J, Bérubé C, Bruneau J, Carrier L, Breton MJ, Falardeau G, Belleau R. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155:555–561.
34. Lacasse Y, Guyatt GH, Goldstein RS. Is there really a controversy surrounding the effectiveness of respiratory rehabilitation? Chest 1998; 114:1–4.
35. Cooper CB. Determining the role of exercise in patients with chronic pulmonary disease. Med Sci Sports Exer 1995; 27:147–157.
36. Guyatt GH, Townsend M, Berman LB, Pugsley SO. Quality of life in patients with chronic airflow limitation. Br J Dis Chest 1987; 81:45–54.
37. Kinsman RA, Yaroush RA, Fernandez E, Dirks JF, Schocket M, Fukuhara J. Symptoms and experiences in chronic bronchitis and emphysema. Chest 1983; 83:755–761.
38. Vallet G, Ahmaïdi S, Serres I, Fabre C, Bourgouin D, Desplan J, Varray A, Préfaut C. Comparison of two training programmes in chronic airflow limitation patients: standardized versus individualized protocols. Eur Respir J 1997; 10:114–122.
39. Jones NL. Approaches to clinical exercise testing. In: Clinical Exercise Testing. Philadelphia: WB Saunders, 1988:123–134.
40. Steele B. Timed walking tests of exercise capacity in chronic cardiopulmonary illness. J Cardiopulmonary Rehabil 1996; 16:25–33.
41. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751–758.
42. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773–778.
43. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s respiratory questionnaire. Am Rev Respir Dis 1992; 145:1321–1327.
44. Bickford LS, Hodgkin JE, McInturff SL. National pulmonary rehabilitation survey update. J Cardiopulmonary Rehabil 1995; 15:406–411.
45. Brooks D, Lacasse Y, Goldstein RS. Pulmonary rehabilitation programs in Canada: a national survey. Can Respir J 1999; 6:55–63.
46. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118:622–629.
47. McGavin CR, Gupta SP, Lloyd EL, McHardy GJR. Physical rehabilitation for the chronic bronchitis: results of a controlled trial of exercises in the home. Thorax 1977; 32:307–311.
48. Cockroft AE, Saunders MJ, Berry G. Randomised controlled trial of rehabilitation in chronic respiratory disability. Thorax 1981; 36:200–203.
49. Lake FR, Henderson K, Briffa T, Openshaw J, Musk AW. Upper-limb and lower-limb exercise training in patients with chronic airflow obstruction. Chest 1990; 97:1077–1082.
50. Alexander MR, Dull WL, Kasik JE. Treatment of chronic obstructive pulmonary disease with orally administered theophylline: a double-blind, controlled study. JAMA 1980; 244:2286–2290.
51. Jaeschke R, Guyatt GH, Singer J, Keller J, Newhouse MT. Mechanism of bronchodilator effect in chronic airflow limitation. Can Med Assoc J 1991; 144:35–39.
52. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48:227–232.
53. Lacasse Y, Wong E, Guyatt GH, Goldstein RS. Health-status measure instruments in chronic obstructive pulmonary disease. Can Respir J 1997; 4:152–164.
54. Guyatt GH, Sackett DL, Cook DJ, for the Evidence-Based Medicine Working Group. Users’ guide to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA 1993; 270:2598–2601.
55. Carter R, Coast JR, Idell S. Exercise training in patients with chronic obstructive pulmonary disease. Med Sci Sport Ex 1992; 24:281–291.
56. Clark CJ. Evaluating the results of pulmonary rehabilitation treatment. In: Casaburi R, Petty TL, eds. Principles and Practice of Pulmonary Rehabilitation. Philadelphia: WB Saunders, 1988:405–414.
57. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994; 331:394–398.
58. Schulz KF. Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias—dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408–412.
59. Moher D, Jones A, Cook DJ, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352:609–613.
60. Herala M. Evaluation of methods for treating obstructive lung disease: mini-review based on a doctoral thesis. Upsala J Med Sci 1993; 38:1–37.
61. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax 1984; 39: 818–822.
62. Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Intern Med 1989; 110:560–566.
63. Louis TA, Lavori PW, Bailar JC, Polansky M. Crossover and self-controlled designs in clinical research. N Engl J Med 1984; 310:24–31.
64. Jaeschke R, Guyatt GH, Willan A, Cook D, Harper S, Morris J, Ramsdale H, Haddon R, Newhouse M. Effect of increasing dose of beta-agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation. Thorax 1994; 49:479–484.
65. Lock SH, Blower G, Prynne M, Wedzicha JA. Comparison of liquid and gaseous oxygen for domiciliary portable use. Thorax 1992; 47:98–100.
66. Cambach W, Chadwick-Straver RVM, Wagenaar RC, van Keimpema ARJ, Kemper HCG. The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. Eur Respir J 1997; 10:104–113.
67. Nishimura K, Koyama H, Ikeda A, Tsukino M, Hajiro T, Mishima M, Izumi T. The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest 1999; 115:31–37.
68. Guyatt G, Sackett D, Taylor W, Chong J, Roberts R, Pugsley S. Determining optimal therapy—randomized trials in individual patients. N Engl J Med 1986; 314:889–892.
69. Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NAM, Wood TE, Donner A. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 1999; 115:38–48.
70. Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D, Keller J. A clinician’s guide for conducting randomized trials in individual patients. Can Med Assoc J 1988; 139:497–503.
71. Patel A, Jaeschke R, Guyatt GH, Keller JL, Newhouse MT. Clinical usefulness on n-of- 1 randomized controlled trials in patients with nonreversible chronic airflow obstruction. Am Rev Respir Dis 1991; 144:962–964.
72. Mahon J, Laupacis A, Donner A, Wood T. Randomised study of n of 1 trials versus standard practice. Br Med J 1996; 312:1069–1074.
73. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J, on behalf of the International COPD Study Group. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351:773–780.
74. Guyatt GH, Sackett DL, Cook DJ, for the Evidence-Based Medicine Working Group. Users’ guide to the medical literature. II. How to use an article about therapy or prevention. B. What are the results and will they help me in caring for my patients? JAMA 1994; 271:59–63.
75. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318:1728–1733.
76. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989; 10:407–415.
77. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996; 49:1215–1219.
78. Redelmeier DA, Goldstein RS, Min ST, Hyland RH. Spirometry and dyspnea in patients with COPD—when small differences mean little. Chest 1996; 109:1163–1168.
79. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155:1278–1282.
80. Jones PW, Lasserson D. Relationship between change in St. George’s Respiratory Questionnaire score and patients’ perception of treatment efficacy after one year of therapy with nedocromil sodium. Am J Respir Crit Care Med 1994; 149:A211.
81. Jones PW, Bosh TK, in association with an international study group. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283–1289.
82. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C, on behalf of an international study group. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10:815–821.
83. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. Br Med J 1998; 316:690–693.
84. Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344:1394–1397.
85. Goldstein RS, Gort EH, Guyatt GH, Feeny D. Economic analysis of respiratory rehabilitation. Chest 1997; 112:370–379.
86. Lacasse Y, Wong E, Guyatt GH. A systematic overview of the measurement properties of the Chronic Respiratory Questionnaire. Can Respir J 1997; 4:131–139.
87. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J 1986; 292:746–750.
88. Walter SD. Methods of reporting statistical results from medical research studies. Am J Epidemiol 1995; 141:896–906.
89. Albert RK, Martin TR, Lewis LW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92:753–758.
90. Glenny RW. Steroids in COPD: the scripture according to Albert [editorial]. Chest 1987; 91:289–290.
91. Makuch RW, Johnson MF. Some issues in the design and interpretation of “negative” clinical studies. Arch Intern Med 1986; 146:986–989.
92. Schuirmann DJ. A comparison of the two one-sided test procedure and the power approach for assessing equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657–680.
93. Detsky AS, Sackett DL. When was a “negative” clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 1985; 145:709–712.
94. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121:200–206.
95. Detsky AS, Sackett DL. Establishing therapeutic equivalency. What is a clinically significant difference? Arch Intern Med 1986; 146:861–862.
96. Tsiatis A. Intent-to-treat analysis. J AIDS 1990; 3(Suppl):S120–S123.
97. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O’Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA, for the Lung Health Study Research Group. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272:1497–1505.
98. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW, for the Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (Prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296–301.
99. Oxman AD, Cook DJ, Guyatt GH for the Evidence-based medicine working group. Users’ guides to the medical literature. VI: How to use an overview. JAMA 1994; 272:1367–1371.
100. L’Abbe KA, Detsky AS, O’Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107:224–233.
101. Lacasse Y, Goldstein RS. Overviews of respiratory rehabilitation in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1999; 54:163–167.
102. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316:450–455.
103. Anello C, Fleiss JL. Exploratory or analytic meta-analysis: should we distinguish between them? J Clin Epidemiol 1995; 48:109–116.
104. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med 1995; 123:873–877.
105. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990; 263:1385–1389.
106. Easterbrook PA, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet 1991; 337:867–872.
107. Glass GV, McGaw, Lee, Smith M, eds. An evaluation of meta-analysis. In: Meta-Analysis in Social Research. Beverly Hills: Sage Publications, 1981:217–231.
108. Villar J, Carrolli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet 1995; 345:772–776.
109. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536–542.
110. Cappelleri JC, Ioannidis JPA, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, Lau J. Large trials vs. meta-analysis of smaller trials: How do their results compare? JAMA 1996; 276:1332–1338.
111. Fleiss JL. The statistical basis of meta-analysis. Stat Meth Med Res 1993; 2:121–145.
112. Der Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7:177–188.
113. Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med 1992; 116:78–84.
114. Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on the efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343:139–142.
115. Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relationship between systematic reviews and practice guidelines. Ann Intern Med 1997; 127:210–216.
116. Smith K, Cook D, Guyatt GH, Madhavan J, Oxman AD. Respiratory muscle training in chronic airflow limitation: a meta-analysis. Am Rev Respir Dis 1992; 145:533–539.
117. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991; 114: 216–223.
118. Cook DJ, Guyatt GH, Laupacis A, Sackett DL, Goldberg RJ. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995; 108:227S–230S.
119. Lacasse Y, Goldstein RS. Scoring evidence of pulmonary rehabilitation in COPD [letter]. Chest 1998; 114:343–344.
120. Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. JAMA 1994; 272:1926–1931.